Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
36. |
ECCT/24/04/04 | TNBC A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF TOBEMSTOMIG/RO7247669 COMBINED WITH NAB-PACLITAXEL COMPARED WITH PEMBROLIZUMAB COMBINED WITH NABPACLITAXEL IN PARTICIPANTS WITH PREVIOUSLY UNTREATED, PD-L1-POSITIVE, LOCALLY-ADVANCED UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER |
Principal Investigator(s) 1. Mansoor Saleh Site(s) in Kenya 1. University of Nairobi - Institute of Tropical and Infectious Diseases (Nairobi City county) 2. International Cancer Institute (Nandi county) 3. The Aga Khan University Hospital - Kenya (Nairobi City county) |
View |
37. |
ECCT/24/04/03 | SMAART-MAP trial Severe Malaria A Research and Trials consortium - Multisite Adaptive Platform trial |
Principal Investigator(s) 1. Prof Kathryn Maitland Maitland Site(s) in Kenya Kilifi County Hospital |
View |
38. |
ECCT/24/04/02 | PEARL RSVt Vaccine Study Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL |
Principal Investigator(s) 1. Dr Fredrick Kipyego Sawe Site(s) in Kenya 1. Walter Reed Army Institute of Research -Kericho Site (Kericho county) |
View |
39. |
ECCT/24/04/01 | B/F/TAF to DTG/3TC Switch Stud Efficacy, Safety and Tolerability of Switching to DTG/3TC Single Tablet Regimen from B/F/TAF in Older Persons Living with HIV in Kenya |
Principal Investigator(s) 1. Loice Achieng Ombajo Site(s) in Kenya 1. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) 2. Kenyatta National Hospital (Nairobi City county) |
View |
40. |
ECCT/24/03/07 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Prof Walter Godfrey Jaoko Site(s) in Kenya 1. KAVI – Institute of Clinical Research (KAVI - ICR) (Nairobi City county) |
View |